CD3AK细胞冻融提取液的抗肿瘤活性研究

为研究CD3AK细胞冻融提取液的抗肿瘤作用,作者采集正常人外周血分离单个核细胞(PBMC),先用抗CD3的单克隆抗体(CD3McAb)和rIL-2诱导和激活,使之成为CD3McAb激活的杀伤细胞(CD3AK),再制备CD3AK的冻融提取液,然后进行体内、外抗肿瘤实验.结果:低剂量的CD3McAb和rIL-2能明显诱导PBMC的活化和增殖;激活后的CD3AK细胞冻融提取液可抑制小鼠肝癌实体瘤细胞H22在小鼠体内生长,其抑瘤率达68.20%(肿瘤局部注射)和60.38%(腹腔注射);在体外实验中,该提取液能有效杀伤K562和Raji瘤细胞,其杀瘤活性分别为83.32%和66.83%.以上研究说明CD3AK细胞冻融提取液有可能成为肿瘤生物治疗的一种新型制剂.

Antitumor Activity of the Lysates Prepared from Anti-CD3 Antibody Activated Killer Cells

This study was directed at the antitumor activity of the lysates prepared from CD 3McAb activated killer cells. We separated the peripheral blood monocytes(PBMC) from normal adults. The PBMC were induced by monoclonal antibody specific for CD 3(CD 3McAb) and activated by rIL 2. The CD 3McAb activated killer cells(CD 3AK) were smashed by ultrasonic wave, along with frozen and thawed three times, then the lysates were obtained by centrifugation. The lysates were tested for antitumor activity in vivo and in vitro. The results revealed that the inhibition rate of the lysates that acted on mice solid tumor hepatoma 22(H22) was 68.20% and the killing activity of the lysates on K562 and Raji were 83.32%, and 66.83% respectively. The results of this experiment suggested that the lysates prepared from CD 3McAb activated killer cells is one of probable agents that might apply to biotherapy for tumors.